ipatherapeutics.com - HYFT Market Value to Book Value Ratio

MindWalk Holdings, Inc. (HYFT) - corporate logo

MindWalk Holdings (HYFT) is accelerating the discovery of orphan disease treatments through high-speed AI-driven biodata analysis. The business relies on a SaaS subscription model for R&D centers, ensuring high margins and stable free cash flow. The current metric is 12.00. This daily price chart confirms that the market has already priced in the modest financial results of this micro-cap while awaiting the launch of corporate modules.

MindWalk Therapeutics (HYFT) - Market Value to Book Value from 09/05/2025 to 10/30/2026
Manufactured product of MindWalk

This indicator measures the market premium over the net asset value, determining the price of one dollar of book capital. Investors utilize this ratio to identify business overvaluation relative to its actual tangible asset base. By analyzing the trend of market capitalization to book value on GURU.Markets, one can promptly capture speculative impulses. For MindWalk Holdings (HYFT), a high premium reflects market expectations regarding its unique AI patents, which is critically important amidst fierce competition with tech behemoths.

Competitor analysis

HLN (Haleon plc) - Market Cap to Net Assets Ratio|KVUE: Market Cap to Book Value Multiple|Market Value to Book Value Ratio Verona Pharma|Jyong Biotech Limited - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio LGND|AMRX (Amneal Corp) - Market Value to Book Value|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|Market Capitalization to Book Value Ratio alvotech.com ALVO|LQDA - Market Value to Book Value Ratio|Market Value to Book Value GLPG (Galapagos N.V.)|ANI Pharma (ANIP) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Afrezza|AMPH (Amphastar Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio pacira.com|Market Cap to Net Assets Ratio SPRY (ARS Pharmaceuticals, Inc.)|TBPH (Theravance Biopharma Inc) - Market Value to Book Value|Market Value to Book Value Ratio Aquestive Pharma AQST|scPharmaceuticals, Inc. (SCPH) - Market-to-Book Ratio|TECX: Market Cap to Net Assets Ratio|tonixpharma.com - Market Cap to Book Value Multiple|SXTC: Market Capitalization to Book Value Ratio|Eupraxia Pharmaceuticals Inc. - Market Value to Book Value|BHST (BioHarvest) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Invizyne EXOZ|Market Value to Book Value Ratio Oramed Pharmaceuticals (ORMP)|ENTX (enterabio.com) - Market Value to Book Value|Market Value to Book Value Ratio ABVC BioPharma, Inc. ABVC|CPIX - Market Cap to Net Assets Ratio|Quantum BioPharma Limited - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value FibroGen Corporation FGEN|Telomir Pharmaceuticals (TELO) - Market Value to Book Value Ratio|Capitalization to Book Value Ratio RANI|SNYR (Synergy CHC Corp.) - Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio RLYB (Rallybio Corp.)|Market Cap to Net Assets Ratio LEXX (Lexaria Bioscience)|Market Cap to Net Assets Ratio Pulmatrix Corporation PULM|Market Capitalization to Book Value Ratio PTHL (Pheton Holdings)|Market Capitalization to Book Value Ratio Aptorum Group Ltd APM|LYRA - Market Value to Book Value Ratio|IBO: Market Value to Book Value Ratio|tnfpharma.com (TNFA) - Market Value to Book Value Ratio|cbdMD (YCBD) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio PRFX|CYTO: Market Value to Book Value|Market Capitalization to Book Value Ratio LIPO|OPTN (OptiNose Inc) - Market Value to Book Value|Market Value to Book Value Ratio Pieris PIRS|Procaps Group Corp (PROC) - Market-to-Book Ratio|PTPI - Market Value to Book Value Ratio|QLI: Market Value to Book Value Ratio|SLRN: Market Capitalization to Book Value Ratio|Capitalization to Book Value Ratio TFFP